{"denoms":[{"counts":[{"groupId":"BG000","value":"402"},{"groupId":"BG001","value":"406"},{"groupId":"BG002","value":"808"}],"units":"Participants"}],"groups":[{"description":"Participants randomized to this arm received pertuzumab 420 milligrams (mg) intravenously (IV) once every 3 weeks (q3w) and trastuzumab 6 milligrams per kilogram (mg/kg) IV q3w, plus docetaxel 75 milligrams per square metre of body surface (mg/m\\^2) IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.","id":"BG000","title":"Pertuzumab + Trastuzumab + Docetaxel"},{"description":"Participants randomized to this arm received placebo IV q3w and trastuzumab 6 mg/kg IV q3w, plus docetaxel 75 mg/m\\^2 IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.","id":"BG001","title":"Placebo + Trastuzumab + Docetaxel"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.94","value":"53.4"},{"groupId":"BG001","spread":"11.35","value":"53.5"},{"groupId":"BG002","spread":"11.14","value":"53.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"402"},{"groupId":"BG001","value":"404"},{"groupId":"BG002","value":"806"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"83"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"362"},{"groupId":"BG001","value":"362"},{"groupId":"BG002","value":"724"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"128"},{"groupId":"BG001","value":"133"},{"groupId":"BG002","value":"261"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"30"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"245"},{"groupId":"BG001","value":"235"},{"groupId":"BG002","value":"480"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"30"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"125"},{"groupId":"BG001","value":"128"},{"groupId":"BG002","value":"253"}],"title":"Asia"},{"measurements":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"152"},{"groupId":"BG002","value":"306"}],"title":"Europe"},{"measurements":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"135"}],"title":"North America"},{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"114"}],"title":"South America"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"184"},{"groupId":"BG001","value":"192"},{"groupId":"BG002","value":"376"}],"title":"Adjuvant or Neo-Adjuvant Therapy"},{"measurements":[{"groupId":"BG000","value":"218"},{"groupId":"BG001","value":"214"},{"groupId":"BG002","value":"432"}],"title":"De Novo"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior Treatment Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"343"},{"groupId":"BG001","value":"336"},{"groupId":"BG002","value":"679"}],"title":"Measurable Disease"},{"measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"87"}],"title":"Non-Measurable Disease"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"42"}],"title":"Not Evaluated"}]}],"description":"A participant was deemed to have measurable disease if they had at least 1 target lesion at screening. Target lesions (maximum of 5 per organ and 10 in total) were selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by imaging techniques or clinically). Any participants with non-target lesions only were deemed to have non-measurable disease. The IRF did not evaluate baseline tumor assessments for any participant without a post-baseline tumor assessment.","paramType":"COUNT_OF_PARTICIPANTS","title":"Independent-Review Facility (IRF)-Determined Disease Status at Screening","unitOfMeasure":"Participants"}],"populationDescription":"ITT population"}